mouse anti il 1r1  (R&D Systems)

Journal: bioRxiv

Article Title: IL-1R1 Blockade Enhances CD40 Agonist-Mediated Immune Responses but Fails to Increase Efficacy or Mitigate Hepatotoxicity in Pancreatic Cancer

doi: 10.1101/2025.02.23.639774

Figure Lengend Snippet: Mice bearing 9-day-old orthotopic PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with the indicated antibodies (200 µg/mouse, intraperitoneal). (a) Bulk transcriptomic analysis of orthotopic PDAC tumors after 2 weeks of treatment initiation (*p < 0.05; unpaired t-test, n = 2 mice/group). (b) Kaplan-Meier survival curves (log-rank test, n = 5-6 mice/group). (c) Tumor growth kinetics in subcutaneous PDAC-bearing mice treated every 3 days with agonistic CD40 antibody, anti-IL-1R1 antibody, their combination, or left untreated (****p < 0.0001; two-way ANOVA, n = 5-8 mice/group). (d) Representative H&E-stained tumor sections showing necrosis after 2 weeks of treatment (n = 3-4 mice/group). (e) Quantification of necrotic areas (**p < 0.01; one-way ANOVA, n = 3-4 mice/group). (f) Flow cytometric analysis of PMN-MDSCs in peripheral blood after 2 weeks of treatment (*p < 0.05; unpaired Student’s t-test, n = 5 mice/group). (g) Volcano plot of differentially expressed genes (DEGs) in subcutaneous PDAC tumors treated with anti-IL-1R1 versus untreated controls (red: upregulated; green: downregulated; 546 up, 530 down; p ≤ 0.05, log2FC ≥ 0). (h–i) Gene Ontology (GO) enrichment analysis of DEGs from (g), showing significantly upregulated (h) and downregulated (i) biological processes. (j) Volcano plot of DEGs comparing combination therapy (CD40 + anti-IL-1R1) versus CD40 monotherapy (524 up, 534 down; p ≤ 0.05, log2FC ≥ 0). (k–l) GO enrichment analysis of DEGs from (j), highlighting upregulated (k) and downregulated (l) pathways. (m) Gene Set Enrichment Analysis (GSEA) plots demonstrating the enrichment of indicated gene sets in the combination therapy group compared to CD40 monotherapy.

Article Snippet: Beginning 9 days after tumor implantation, subcutaneous and orthotopic PDAC-bearing mice were treated with anti-IL-1R1 (Clone JAMA-147, BioXCell) or isotype control antibodies (BioXCell) administered intraperitoneally.

Techniques: Imaging, Staining

Journal: bioRxiv

Article Title: IL-1R1 Blockade Enhances CD40 Agonist-Mediated Immune Responses but Fails to Increase Efficacy or Mitigate Hepatotoxicity in Pancreatic Cancer

doi: 10.1101/2025.02.23.639774

Figure Lengend Snippet: Mice bearing 9-day-old subcutaneous PDAC tumors were treated as indicated. (a-b) Serum ALT (a) and AST (b) levels were measured 48 hours after treatment initiation using the COBAS INTEGRA 400 Plus analyzer. *p < 0.01, Wilcoxon non-parametric test; n = 6-9 mice/group. Data represent results combined from two independent experiments. (c) Representative H&E-stained liver histology images from mice collected one week after treatment initiation (n = 3 mice/group, two treatments administered). (d) Cumulative quantification of immune infiltration and histological changes (n = 3 mice/group). (e-f) Serum ALT and AST levels measured after 9 days (e) and 3 weeks (f) of treatment initiation. Combo: agonistic CD40 + anti-IL-1R1 antibody. (g-h) Transcriptomic profiling of the liver from PDAC-bearing mice one week after treatment initiation (two treatments total). KEGG pathway enrichment analysis comparing agonistic CD40 vs. no treatment (g) and combo vs. agonistic CD40 (h). The dot plot highlights pathways associated with liver function, toxicity, and immune infiltration. Dot size represents the number of genes involved (Count), while color intensity reflects statistical significance (−log10 p-value). Upregulated pathways are marked with upward triangles (▴), and downregulated pathways with downward triangles (▾). Pathways with p-value < 0.05 are considered significantly enriched.

Article Snippet: Beginning 9 days after tumor implantation, subcutaneous and orthotopic PDAC-bearing mice were treated with anti-IL-1R1 (Clone JAMA-147, BioXCell) or isotype control antibodies (BioXCell) administered intraperitoneally.

Techniques: Staining

Journal: bioRxiv

Article Title: IL-1R1 Blockade Enhances CD40 Agonist-Mediated Immune Responses but Fails to Increase Efficacy or Mitigate Hepatotoxicity in Pancreatic Cancer

doi: 10.1101/2025.02.23.639774

Figure Lengend Snippet: Mice bearing 9-day-old subcutaneous PDAC tumors were treated as indicated. Graphs show tumor growth at indicated time points. Figure: Tumor growth kinetics in mice bearing 9-day-old subcutaneous PDAC tumors treated as indicated. Tumor area (mm 2 ) was measured over 27 days following treatment initiation. Treatment groups included: no treatment (NO Tx), anti-Ly6G, agonistic CD40 (AgoCD40), AgoCD40 combined with anti-Ly6G, and AgoCD40 combined with anti-IL-1R1. Data represent mean ± SEM (n = 6-9 mice per group). Statistical significance was determined by two-way ANOVA with Tukey’s post hoc test. ***p < 0.001, ****p < 0.0001.

Article Snippet: Beginning 9 days after tumor implantation, subcutaneous and orthotopic PDAC-bearing mice were treated with anti-IL-1R1 (Clone JAMA-147, BioXCell) or isotype control antibodies (BioXCell) administered intraperitoneally.

Techniques:

Journal: Brain, Behavior, & Immunity - Health

Article Title: LPS-induced acute neuroinflammation, involving interleukin-1 beta signaling, leads to proteomic, cellular, and network-level changes in the prefrontal cortex of mice

doi: 10.1016/j.bbih.2023.100594

Figure Lengend Snippet: The upregulation of IL-1β and IL-1R1 after LPS treatment shows a similar time course as the neuroinflammation-related EEG changes. (A) The concentration of IL-1β measured in PFC tissue homogenates at different time points after LPS injection. The data show a significant increase 4 h after the treatment and then a rapid decrease. (B) Serum levels of IL-1β also showed a significant increase 4 h after LPS injection; however, the following decrease was more gradual over time. The concentration of IL-1β was measured by a magnetic bead-based immunoassay. (C) Western blot analysis of PFC IL-1R1 expression after LPS treatment. Densitometry analysis of immunoblots from PFC tissue homogenates (left panel) revealed a significant increase in IL-1R1 levels at 4 h after LPS treatment and then a gradual decrease over time (right panel). Control and 4 h LPS data were statistically compared using two-sample t -test (n = 5 mice for each group). Data are presented as mean ± SD. * P < 0.05, ** P < 0.01.

Article Snippet: The blots were blocked with 5.0% BSA in Tris-buffered saline with 0.05% Tween-20 (TBS-T) for 1 h. The membranes were then incubated overnight at 4 °C in the blocking buffer with goat anti-IL-1R1 antibody (1:500 dilution, AF771-SP, R&D Systems, Minneapolis, MN, USA).

Techniques: Concentration Assay, Injection, Bead-based Assay, Western Blot, Expressing, Control